The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
724 - We have an HCP piece approved by PAAB to be used as a print Leave-Behind. We would like to use a part of the content (unchanged) for a digital advertisement. Does is require to be submitted to PAAB as a new file?
-
Yes. PAAB reviews pieces in their entirety. Reproduction of part of a piece would not be representative of the full review and may not meet the full requirements of the code. The digital advertisement should be submitted for review as a new piece. For further information, we refer you to the “Digitizing Print APS” section of the PAAB Guidance Document for the Submission Process.
